Neuropathy resembling CIDP in patients receiving tumor necrosis factor-α blockers
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Tumor necrosis factor-α (ΤΝFα) blockers are effective in the treatment of inflammatory arthritis but can induce autoimmune disorders including multiple sclerosis. Described are two patients who developed chronic inflammatory demyelinating polyneuropathy after initiation of anti-TNFα treatment.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Emily Gilmore and Dr. Rachel Beekman
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Article
Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathiesH. Stephan Goedee, W. Ludo van der Pol, Jan-Thies H. van Asseldonk et al.Neurology, December 07, 2016 -
Article
NK cell markers predict the efficacy of IV immunoglobulins in CIDPAnne K. Mausberg, Maximilian K. Heininger, Gerd Meyer Zu Horste et al.Neurology: Neuroimmunology & Neuroinflammation, October 02, 2020 -
Article
Chronic inflammatory demyelinating polyneuropathyClinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathyKenneth C. Gorson, Gregory Allam, Allan H. Ropper et al.Neurology, February 01, 1997 -
Article
Recovery of the T-cell repertoire in CIDP by IV immunoglobulinsAnne K. Mausberg, Mareike Dorok, Mark Stettner et al.Neurology, December 26, 2012


